Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy.

M M Mehndiratta1, R A Hughes

  • 1Neurology, GB Pant Hospital, D-II / 103, Kidwai Nagar-West, New Delhi, India, 110023. mmehndi@ndf.vsnl.net.in

The Cochrane Database of Systematic Reviews
|March 1, 2002
PubMed
Summary

Corticosteroids may improve impairment in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). However, a single trial showed weak evidence, and long-term risks and benefits require further study.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spinal A V M : unusual association.

Neurology India·2018
Same author

Insulinoma presenting with dementia and hemiplegia.

Neurology India·2018
Same author

Corrigendum to "An amino acid depleted cell-free protein synthesis system for the incorporation of non-canonical amino acid analogs into proteins" [J. Biotechnol. 178 (2014) 12-22].

Journal of biotechnology·2016
Same author

Transformation of truncated gold octahedrons into triangular nanoprisms through the heterogeneous nucleation of silver.

Nanoscale·2015
Same author

Suppressor cells and treatment of multiple sclerosis.

Immunology today·2014
Same author

Hoover's sign: Clinical relevance in Neurology.

Journal of postgraduate medicine·2014

Area of Science:

  • Neurology
  • Immunology
  • Clinical Trials

Background:

  • Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an autoimmune peripheral neuropathy.
  • Corticosteroids are commonly used and expected to benefit CIDP patients.
  • Non-randomized studies suggest corticosteroid efficacy in CIDP.

Purpose of the Study:

  • To evaluate the efficacy of corticosteroids for treating CIDP.
  • Assess the impact of corticosteroids on disability and impairment in CIDP patients.

Main Methods:

  • Searched the Cochrane Neuromuscular Disease Group register for randomized controlled trials (RCTs).
  • Included all randomized or quasi-randomized trials of corticosteroids or adrenocorticotropic hormone for CIDP.
  • Primary outcome was change in disability at 12 weeks; secondary outcomes included impairment, nerve conduction velocity, and side effects.

Related Experiment Videos

Main Results:

  • One RCT with 35 participants (19 treated, 16 controls) showed greater improvement in impairment with corticosteroids after 12 weeks.
  • Non-randomized studies also suggest beneficial effects of steroids.

Conclusions:

  • A single RCT provides weak evidence for oral corticosteroids reducing impairment in CIDP.
  • Long-term risks and benefits of corticosteroids in CIDP remain inadequately studied.
  • Further research is needed to establish optimal corticosteroid use in CIDP management.